LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

2022 update on the scientific premise and clinical trials for IL‐15 agonists as cancer immunotherapy

Photo by nci from unsplash

Diverse cytokines and their receptors on immune cells constitute a highly complex network in the immune system. Some therapeutic cytokines and their derivatives have been approved for cancer treatment. IL‐15… Click to show full abstract

Diverse cytokines and their receptors on immune cells constitute a highly complex network in the immune system. Some therapeutic cytokines and their derivatives have been approved for cancer treatment. IL‐15 is an immune‐regulating cytokine with multiple functions, among which the function of activating the immunity of cancer patients has great potential in cancer immunotherapy. In this review, we introduce the functions of IL‐15 and discuss its role in regulating the immune system in different immune cells. Meanwhile, we will address the applications of IL‐15 agonists in cancer immunotherapy and provide prospects for the next generation of therapeutic designs. Although many challenges remain, IL‐15 agonists offer a new therapeutic option in the future direction of cancer immunotherapy.

Keywords: 2022 update; agonists cancer; cancer immunotherapy; cancer; update scientific

Journal Title: Journal of Leukocyte Biology
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.